Treatment and prevention of secondary CNS lymphoma

S. Nagpal, M. J. Glantz, Lawrence Recht

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Central nervous system (CNS) involvement in non-Hodgkin lymphoma is a serious, potentially preventable complication that can occur in 5 to 10% of patients. Its occurrence is directly correlated with pathologic aggressiveness and ranges from less than 3% in the indolent, less-aggressive histologies to as high as 50% in the very aggressive ones such as Burkitt lymphoma. Aggressive treatment once detected can improve neurologic outcome, but because it is often associated with contemporaneous systemic relapse, is rarely associated with long-term survival. Preventing its occurrence, therefore, remains an important goal of initial treatment. Despite there being some suggestive evidence that the addition of systemic rituximab and several intracerebrospinal fluid chemotherapy regimens may have decreased the incidence of CNS involvement, both optimal selection of those patients who should receive prophylaxis as well as the best prophylactic regimen remain active areas of investigation.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalSeminars in Neurology
Volume30
Issue number3
DOIs
StatePublished - Jul 6 2010

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Treatment and prevention of secondary CNS lymphoma'. Together they form a unique fingerprint.

  • Cite this